Neoadjuvant Nivolumab and Ipilimumab for Resectable Stage III Melanoma: The New Standard of Care?

被引：0
|
作者：
Miura, John T. [1 ]
Karakousis, Giorgos C. [1 ]
机构：
[1] Hosp Univ Penn, Div Endocrine & Oncol Surg, Philadelphia, PA 19104 USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2025年 / 32卷 / 03期
关键词：
D O I：
10.1245/s10434-024-16807-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1394 / 1396
页数：3
相关论文
共 50 条
  • [21] Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches
    Tarhini, Ahmad A.
    Castellano, Ella
    Eljilany, Islam
    CANCER JOURNAL, 2024, 30 (02): : 54 - 70
  • [22] Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma
    Su, Y.
    Lin, Y.
    Hsiao, C.
    Ou, D.
    Chen, S.
    Wu, Y.
    Lee, W.
    Lin, J.
    Hsu, C.
    Ho, M.
    Lu, L.
    Wu, T.
    Lai, S.
    Chao, Y.
    Chou, T.
    Yen, C.
    Chen, L.
    Shan, Y.
    Cheng, A.
    Hsu, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S141 - S141
  • [23] Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials.
    Versluis, Judith M.
    Sikorska, Karolina
    Rozeman, Elisa A.
    Menzies, Alexander M.
    Eriksson, Hanna
    Klop, W. Martin. C.
    Saw, Robyn P. M.
    Van de Wiel, Bart A.
    Scolyer, Richard A.
    Van Thienen, Johannes V.
    Mallo, Henk
    Gonzalez, Maria
    Acosta, Alex Torres
    Grijpink-Ongering, Lindsay G.
    Van der Wal, Anja
    Haanen, John B. A. G.
    Van Akkooi, Alexander Christopher Jonathan
    Long, Georgina V.
    Blank, Christian U.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Neoadjuvant Ipilimumab/Nivolumab combination in locally advanced or oligometastatic melanoma
    Ferrucci, Pier Francesco
    Lanfrancone, Luisa
    Mazzarella, Luca
    Nezi, Luigi
    Duso, Bruno Achutti
    Manzo, Teresa
    Lotti, Fiorenza
    Gandini, Sara
    Orsolini, Gianmarco
    Pennacchioli, Elisabetta
    Gnagnarella, Patrizia
    Fierro, Maria Teresa
    Senetta, Rebecca
    Riviello, Concetta
    Caliendo, Virginia
    Quaglino, Pietro
    Mazzarol, Giovanni
    Bonizzi, Giuseppina
    Cocorocchio, Emilia
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (SUPPL 1)
  • [25] Adjuvant Nivolumab or Ipilimumab + Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab
    Tahsin M. Khan
    Martha E. Teke
    Giorgos C. Karakousis
    John T. Miura
    Robert M. Brody
    Jonathan M. Hernandez
    Tara C. Mitchell
    Annals of Surgical Oncology, 2022, 29 : 2771 - 2772
  • [26] Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma
    Zech, Henrike B.
    Moeckelmann, Nikolaus
    Boettcher, Arne
    Muenscher, Adrian
    Binder, Mascha
    Vettorazzi, Eik
    Bokemeyer, Carsten
    Schafhausen, Philippe
    Betz, Christian S.
    Busch, Chia-Jung
    FUTURE ONCOLOGY, 2020, 16 (36) : 3035 - 3043
  • [27] BRAF Inhibitors for Neoadjuvant Treatment in Irresectable or Marginally Resectable Stage III Melanoma
    Zippel, D.
    Benami, E.
    Shapira-Frommer, R.
    Markel, G.
    Nissan, A.
    Gutman, H.
    Schachter, J.
    Schneebaum, S.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S122 - S122
  • [28] Ipilimumab/Nivolumab Is the New Standard of Care in Metastatic Renal Cell Carcinoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (01) : 11 - 12
  • [29] Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
    Reijers, I.
    Dimitriadis, P.
    Menzies, A. M.
    Kapiteijn, E.
    Van der Veldt, A. A. M.
    Suijkerbuijk, K. P. M.
    Hospers, G. A. P.
    Van Houdt, W.
    Saw, R.
    Broeks, A.
    Cornelissen, S.
    Grijpink-Ongering, L.
    Pennington, T.
    Colebatch, A.
    de Wiel, B. van
    Scolyer, R.
    van Akkooi, A. C. J.
    Long, G. V.
    Blank, C. U.
    ANNALS OF ONCOLOGY, 2023, 34 : S660 - S660
  • [30] Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma
    LaPelusa, Michael
    Chamseddine, Shadi
    Cao, Hop Sanderson Tran
    Xiao, Lianchun
    Hasanov, Elshad
    Bhosale, Priya
    Amin, Hesham M.
    Mohamed, Yehia I.
    Gok Yavuz, Betul
    Sakr, Yara
    Xu, Li
    Hu, Ian
    Lee, Sunyoung S.
    Sakamuri, Divya
    Jindal, Sonali
    Nguyen, Van
    Curran, Michael A.
    Sun, Ryan
    Rashid, Asif
    Duda, Dan Gabriel
    Sharma, Padmanee
    Qayyum, Aliya
    Kaseb, Ahmed Omar
    ONCOLOGY, 2024,
12345